A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender

Joyce, Peter R.; Mulder, Roger; Luty, Suzanne E.; McKenzie, Janice M.; Rae, Alma M.

doi:10.1034/j.1600-0447.2003.00120.x

Cited by 72 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was significantly more improvement in the over 40 years age group than in the under 39 years age group. Recently, some investigators reported that noradrenergic antidepressants were more likely than SSRIs to produce a response in middle-aged and elderly patients (Navarro et al, 2001;Joyce et al, 2003;Morishita and Arita, 2004;Thase et al, 2005). However, the risk of cardiovascular disease and/or hypertension is increased in such patients, and increased noradrenergic activity increases the risk of such conditions.…”

Section: Discussionmentioning

confidence: 94%

Predictors of response to sertraline in patients with major depression

Morishita

Kinoshita

2008

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Predictors of response to sertraline in patients with major depression

Morishita

Kinoshita

2008

Human Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…It is also possible that fluoxetine selectively targets negative consequences of stress that just happen to be more prevalent in females. One of the predictions from these results is that women should be more responsive to SSRIs than men; this is indeed the case in depressed patients (Martenyi et al 2001;Joyce et al 2003).…”

Section: Antidepressants and Learning In Males Versus Femalesmentioning

confidence: 90%

Males and females respond differently to controllability and antidepressant treatment

Leuner¹,

Mendolia-Loffredo²,

Shors³

2004

Biological Psychiatry

View full text Add to dashboard Cite

Background-Women are much more likely to suffer from stress-related mental illness than men; yet few, if any, animal models for such sex differences exist. Previously, we reported that exposure to an acute stressor enhances learning in male rats yet severely impairs learning in female rats. Here, we tested whether these opposite effects in males versus females could be prevented by establishing control over the stressor or by antidepressant treatment.

show abstract

“…Both Korstein et al (2000) and Joyce et al (2003) reported that men responded less well to SSRIs such as sertraline and fluoxetine than to TCAs. In these studies, the response rate of male patients to these drugs was about 40-45%, quite similar to the response rate of 46% in this study…”

Section: Efficacy Onset and Timing Of Clinical Actionsmentioning

confidence: 99%

Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression

Katz

Tekell

Bowden

et al. 2003

Neuropsychopharmacol

234

153

View full text Add to dashboard Cite

This study was aimed at resolving the time course of clinical action of antidepressants (ADs) and the type of early behavioral changes that precede recovery in treatment-responsive depressed patients. The first goal was to identify, during the first 2 weeks of treatment, the onset of clinical actions of the selective serotonin reuptake inhibitor (SSRI), paroxetine, and the selective noradrenergic reuptake inhibitor, desipramine (DMI). The second aim was to test the hypothesis that the two pharmacologic subtypes would induce different early behavioral changes in treatment-responsive patients. The design was a randomized, parallel group, placebo-controlled, double-blind study for 6 weeks of treatment following a 1-week washout period. The study utilized measures of the major behavioral components of the depressive disorder as well as overall severity. The results indicated that the onset of clinical actions of DMI ranged from 3 to 13 days, averaged 13 days for paroxetine, and was 16-42 days for placebo. Furthermore, as hypothesized, the different types of ADs initially impacted different behavioral aspects of the disorder. After 1 week of treatment, DMI produced greater reductions in motor retardation and depressed mood than did paroxetine and placebo, and this difference persisted at the second week of treatment. Early improvement in depressed mood-motor retardation differentiated patients who responded to DMI after 6 weeks of treatment from those that did not. Paroxetine initially reduced anxiety more in responders than in nonresponders, and by the second week, significantly improved depressed mood and distressed expression in responders to a greater extent. Depressed patients who responded to placebo showed no consistent early pattern of behavior improvement. Early drug-specific behavioral changes were highly predictive of ultimate clinical response to the different ADs, results that could eventually be applied directly to clinical practice.

show abstract

A differential response to nortriptyline and fluoxetine in melancholic depression: the importance of age and gender

Abstract: Age and gender appear to be critical variables in understanding differential antidepressant responses to tricyclic antidepressants and selective serotonin reuptake inhibitors in melancholic depression.

Cited by 72 publications

References 23 publications

Predictors of response to sertraline in patients with major depression

Predictors of response to sertraline in patients with major depression

Males and females respond differently to controllability and antidepressant treatment

Onset and Early Behavioral Effects of Pharmacologically Different Antidepressants and Placebo in Depression

Contact Info

Product

Resources

About